S. Res. 499 is a nonbinding Senate resolution that establishes a Creutzfeldt-Jakob Disease (CJD) Awareness Day and expresses the Senate’s support for educating the public about this rare, fatal prion disorder.
The resolution collects background findings on CJD’s clinical course, surveillance needs, and potential animal-to-human prion risks and specifically highlights the role of the National Prion Disease Pathology Surveillance Center in monitoring human prion diseases.
The resolution does not create new regulatory obligations or funding streams; it signals congressional recognition of surveillance gaps, encourages attention to postmortem diagnostic capacity, and frames CJD as a public-health matter linked conceptually to chronic wasting disease (CWD) in cervids and broader dementia research. For practitioners, the text is a policy marker that may shape outreach, research priorities, and requests for agency action without changing legal authority or appropriations.
At a Glance
What It Does
The resolution designates an awareness day for CJD, lists findings about incidence, clinical features, and surveillance needs, and formally supports awareness efforts and the activities of the National Prion Disease Pathology Surveillance Center. It does not appropriate funds or create enforceable mandates.
Who It Affects
Families of CJD patients, researchers and laboratories that diagnose prion diseases, public-health surveillance programs, and state agencies tracking chronic wasting disease in wildlife. The resolution is primarily symbolic but could influence research and public-health briefing priorities.
Why It Matters
By elevating CJD in congressional findings, the resolution signals a legislative interest in prion surveillance and diagnostic capacity, which may increase agency attention and stakeholder requests for funding, laboratory support, or expanded surveillance protocols despite remaining nonbinding.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S. Res. 499 is a single-purpose, nonbinding Senate resolution that supports a Creutzfeldt-Jakob Disease (CJD) Awareness Day and documents why Congress should care about prion diseases.
The preamble recites clinical features of CJD — from early memory and coordination problems to rapid deterioration and death — and frames the disease as rare but lethal. The resolution emphasizes that CJD progresses quickly, imposes heavy burdens on patients and caregivers, and requires timely diagnosis (often confirmed postmortem).
The text highlights epidemiology: it cites incidence estimates and the breakdown of sporadic, genetic, and acquired cases to show that most human CJD is sporadic, with very few cases attributable to known exposures. The resolution draws a direct line to animal prion diseases by noting concerns about bovine spongiform encephalopathy (BSE) and chronic wasting disease (CWD) in deer, elk, and moose, and it stresses the importance of surveillance to detect any transmission signals from animals to humans.A central operational point in the resolution is the spotlight on the National Prion Disease Pathology Surveillance Center as the only U.S. laboratory-based organization that monitors human prion diseases.
The resolution argues that continued postmortem brain examination and laboratory monitoring are critical to evaluate whether CWD or other animal prion diseases have crossed into humans. It also notes that prion-disease study can inform Alzheimer’s and related-dementia research and that caregiver research from ADRD could be applied to prion disease support needs.Finally, while the resolution declares support for awareness activities and recognizes the importance of public education, it does not direct agencies to take specific actions or allocate funds.
Its practical effect is symbolic: it aggregates scientific and public-health concerns into formal congressional recognition, which stakeholders can cite when lobbying for surveillance funding, diagnostic capacity, or research initiatives.
The Five Things You Need to Know
The resolution designates a single awareness day for Creutzfeldt-Jakob Disease and directs the Senate to support the goals and ideals of that day.
The bill cites U.S. incidence estimates of approximately 1–2 cases per 1,000,000 people annually, roughly 600 cases per year, with about 85% classified as sporadic, 10–15% genetic, and under 1% acquired.
It identifies the National Prion Disease Pathology Surveillance Center as the only U.S. laboratory-based organization that monitors human prion diseases and emphasizes continued postmortem brain-tissue examination.
The resolution explicitly links human-prion surveillance to concerns about animal prion diseases, noting CWD has been detected in cervids across more than 36 states and all four U.S. regions.
S. Res. 499 is nonbinding: it expresses support and recognition but does not create funding, regulatory duties, or new statutory authorities for federal agencies.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Narrative justification and scientific findings
The preamble compiles epidemiology, clinical presentation, and public-health rationale to justify the awareness day. Practically, these clauses serve as the resolution’s evidence base: they recite statistics on incidence and mortality, describe symptoms and prognosis, and connect human prion concerns to animal prion diseases (BSE and CWD). For stakeholders, these findings can be cited in testimony, grant applications, or advocacy letters to underline a congressional awareness of surveillance gaps.
Emphasis on surveillance, postmortem testing, and the National Prion Disease Pathology Surveillance Center
This provision singles out continued prion disease surveillance—especially postmortem brain-tissue examination—as imperative, and names the National Prion Disease Pathology Surveillance Center as the only U.S. laboratory-based monitor of human prion diseases. Operationally, that endorsement increases visibility for the Center and may translate into requests for expanded diagnostic capacity, even though the resolution does not appropriate funds or alter lab authorities.
Cross-cutting research and caregiver supports
The resolution notes that Alzheimer’s and related-dementia research and caregiver-service models could be applied to prion diseases. This is an explicit invitation for researchers and funders to consider prion disease within broader neurodegenerative research frameworks, which could influence funding priorities and the design of caregiver interventions despite the resolution’s symbolic nature.
Formal support for awareness day and recognition of importance
The operative clauses do two things: (1) they state that the Senate supports the goals and ideals of a Creutzfeldt-Jakob Disease Awareness Day, and (2) they formally recognize the importance of raising awareness about CJD. There is no directive language for agencies, no appropriation, and no regulatory change; the mechanics are declarative and intended to elevate the issue on the public and policy agendas.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Families and caregivers of CJD patients — the resolution raises visibility for a rapidly progressive disease, which can help attract attention to support services, bereavement resources, and research funding proposals targeted at caregiver burden.
- Prion researchers and neuropathology centers — by naming surveillance needs and the National Prion Disease Pathology Surveillance Center, the resolution strengthens the case researchers can make for increased funding, sample-sharing, and expanded diagnostic capacity.
- Public-health surveillance programs at state and federal levels — the congressional recognition may prompt agencies to prioritize prion surveillance in planning documents and grant solicitations, improving coordination on CWD monitoring and human-prion detection.
- ADRD (Alzheimer’s and related dementias) research community — the resolution’s call to apply ADRD caregiver and health-services research to prion diseases highlights opportunities for cross-disciplinary grants and pilot programs.
Who Bears the Cost
- National Prion Disease Pathology Surveillance Center and diagnostic labs — if awareness leads to increased specimen submissions or surveillance expectations, labs may face higher workloads and costs without accompanying appropriations.
- State wildlife and public-health agencies tracking CWD — elevated attention could translate into requests for expanded testing, monitoring, and public reporting, increasing operational demands at the state level.
- Federal agencies and grant programs — while the resolution does not allocate funds, program managers may face political and stakeholder pressure to re-prioritize limited grant dollars toward prion-related surveillance or research.
- Hospitals and clinicians — increased public awareness could lead to more clinical consultations and diagnostic referrals for rapidly progressive dementias, creating downstream demands on specialty services and neuropathology consultation.
Key Issues
The Core Tension
The central dilemma is between raising urgent public and scientific attention to a rare, lethal condition (which can catalyze funding and surveillance improvements) and creating expectations for action that the resolution neither funds nor authorizes; increasing awareness without matched diagnostic and public-health capacity risks straining labs, unsettling the public about uncertain animal-to-human transmission risks, and funneling limited resources away from other public-health priorities.
The resolution stitches together scientific concerns and public-health priorities without creating authority or funding. That approach raises implementation questions: naming surveillance needs and a single national center creates expectations that someone will expand diagnostic and monitoring capacity, but the resolution contains no mechanism to resource that expansion.
Increased awareness can improve case ascertainment but may also produce more specimen referrals and diagnostic burdens for a lab network already constrained by staff and biosafety requirements. The bill also frames CWD as a cross-species concern; however, the science on CWD transmission to humans remains unresolved, and heightened public focus could provoke policy demands (wildlife culling, hunting advisories, meat-processing rules) that the resolution neither evaluates nor empowers.
Another practical tension is between symbolic congressional recognition and the realities of surveillance. The resolution calls for postmortem brain examination as a critical surveillance tool, yet postmortem diagnostics raise consent, logistical, and biosafety hurdles.
If awareness drives demand for postmortem testing, states and hospitals will confront legal and operational steps (next-of-kin consent, biosafety protocols, shipping and storage of infectious tissue) that require funding and guidance absent from the text.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.